Last updated on December 2019

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Coronary Artery Disease | Coronary heart disease
  • Age: Between 50 - 79 Years
  • Gender: Male or Female

Inclusion criteria:

  1. Age: Adult subjects 50 (men) or 55 (women) to 80 years of age (either sex)
  2. Low-density lipoprotein cholesterol (LDL-C) 100 mg/dL ( 2.6 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL) 130 mg/dL ( 3.4 mmol/L) at screening, after 4 weeks of optimized lipidlowering therapy
  3. Evidence of at least one of the following at screening (without prior myocardial infarction or stroke):
  4. Significant coronary artery disease (CAD) B. Significant atherosclerotic cerebrovascular disease C. Significant peripheral arterial disease D. Diabetes mellitus
  5. At least 1 high-risk feature

Exclusion criteria

  • MI or stroke prior to randomization
  • Coronary artery bypass grafting (CABG) 3 months prior to screening
  • Estimated glomerular filtration rate (eGFR) 15 mL/min/1.73 m
  • Uncontrolled or recurrent ventricular tachycardia
  • Atrial fibrillation not on anticoagulation therapy
  • Uncontrolled hypertension (sitting systolic blood pressure 180 mmHg or diastolic blood pressure 110 mmHg) at screening
  • Fasting triglycerides 500 mg/dL (5.7 mmol/L) at screening
  • Last measured left-ventricular ejection fraction 30% or New York Heart Association (NYHA) Functional Class III/IV

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.